Loading…
Eikon Therapeutics, Inc. is projected to decline to $10.28 by 2027, a -3% move from its current price of $10.58. EIKN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $10.08 | $10.59 | $11.13 | +0.10% |
| Jul 14 | $9.88 | $10.60 | $11.37 | +0.21% |
| Jul 15 | $9.74 | $10.61 | $11.57 | +0.31% |
| Jul 16 | $9.62 | $10.62 | $11.73 | +0.41% |
| Jul 17 | $9.52 | $10.63 | $11.88 | +0.51% |
| Jul 18 | $9.43 | $10.65 | $12.02 | +0.62% |
| Jul 19 | $9.34 | $10.66 | $12.15 | +0.72% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.34 | $10.66 | $12.15 | +0.72% |
| Week 2 | $8.91 | $10.73 | $12.92 | +1.45% |
| Week 3 | $8.61 | $10.81 | $13.57 | +2.18% |
| Week 4 | $8.37 | $10.89 | $14.16 | +2.91% |
| Week 5 | $8.18 | $10.97 | $14.71 | +3.65% |
| Week 6 | $8.01 | $11.05 | $15.24 | +4.40% |
| Week 7 | $7.86 | $11.13 | $15.75 | +5.15% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Eikon Therapeutics, Inc. (EIKN) is a clinical biopharmaceutical company based in the United States. It develops medicines to address serious unmet medical needs.
Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses. EIK1003 and EIK1004 are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor.
The company was incorporated in 2019 and is based in Millbrae, California.
Eikon Therapeutics, Inc. trades under the symbol EIKN and is currently priced at $10.72 per share. It has a market capitalization of $580.37M and ranks 2934 in market size.
Forecasts show a path of evolving value, with the 2026 average price at $10.72 (0% ROI, NEUTRAL sentiment) and the 2027 average at $10.36 (-3.3% ROI, NEUTRAL sentiment). From 2028 onward, forecasts flip to a bullish trajectory, with 2028 average $13.92 (29.9% ROI) and 2029 average $17.15 (60% ROI).
The outlook continues through 2030 with an average of $16.67 (55.5% ROI) and 2031 at $16.08 (50% ROI), then 2032 at $15.42 (43.9% ROI) and 2033 at $15.97 (49% ROI). The sequence extends to 2034 with $17.00 (58.6% ROI), 2035 with $21.18 (97.5% ROI), 2040 with $21.30 (98.7% ROI), and 2050 with $48.61 (353.5% ROI). The sentiment remains BULLISH across the long horizon for many years.
A major floor 43.5% below — a decisive break under it would weaken the trend.
The nearest floor, 21.0% below — buyers have tended to step in here.
The nearest ceiling, 23.3% above — a clean break opens room to run.
A major ceiling 45.1% above — clearing it would confirm fresh momentum.
Key EIKN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EIKN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.23 | Sell | $11.14 | Sell |
| MA 10 | $11.82 | Sell | $11.21 | Sell |
| MA 20 | $10.59 | Sell | $10.90 | Sell |
| MA 50 | $10.43 | Buy | $10.71 | Sell |
| MA 100 | $11.20 | Sell | $11.32 | Sell |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.66 | Neutral |
| Stoch RSI (14) | 4.21 | Buy |
| CCI (20) | -0.54 | Neutral |
| Williams %R (14) | -69.77 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | 11.25 | Buy |
| Bollinger %B (20,2) | 0.50 | Neutral |
| Stochastic %K (14) | 30.23 | Neutral |
| TRIX (15) | 0.53 | Buy |
| Awesome (5,34) | 0.94 | Buy |
| Ultimate (7,14,28) | 34.23 | Neutral |
| Momentum (10) | 0.73 | Buy |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 10.58 | Sell |
| ADX (14) | 14.67 | Neutral |
| ATR (14) | 0.53 | Info |
The near-term technical picture is NEUTRAL. The RSI(14) is 50, indicating balanced momentum, and the 50-day simple moving average sits at $10.34.
Near-term support is at $8.36 and resistance at $13.05, defining a chart that could drift between those levels in the near term. The 30-day price range spans from $7.69 to $14.94, illustrating a broader, twice-monthly swing.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.36 | $10.58 | $16.21 | 0% | Neutral | |
| $6.87 | $10.28 | $16.66 | -3% | Neutral | |
| $8.26 | $13.57 | $23.84 | +28% | Bullish | |
| $9.36 | $16.69 | $31.17 | +58% | Bullish | |
| $8.54 | $16.46 | $32.29 | +56% | Bullish | |
| $7.58 | $15.73 | $32.21 | +49% | Bullish | |
| $6.76 | $15.03 | $31.95 | +42% | Bullish | |
| $7.10 | $15.78 | $34.66 | +49% | Bullish | |
| $7.45 | $16.56 | $37.49 | +57% | Bullish | |
| $9.25 | $20.55 | $47.26 | +94% | Bullish | |
| $9.30 | $20.68 | $47.55 | +95% | Bullish | |
| $21.28 | $47.30 | $108.79 | +347% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $8.36 | $10.58 | $12.98 | +0.00% |
| August 2026 | $8.88 | $10.99 | $14.30 | +3.87% |
| September 2026 | $9.20 | $11.62 | $15.55 | +5.72% |
| October 2026 | $8.72 | $11.20 | $15.34 | -3.59% |
| November 2026 | $8.36 | $10.91 | $15.23 | -2.61% |
| December 2026 | $8.62 | $11.41 | $16.21 | +4.56% |
Click any year to see its month-by-month EIKN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, EIKN could reach as high as $16.21, with a base case around $10.58 and support toward $8.36 — roughly 0% from $10.58. Price action looks broadly range-bound.
Expect EIKN to range from $6.87 to $16.66 through 2027. The $10.28 average target implies a -3% move from current prices. That is -3% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The EIKN price prediction for 2028 points to an average of $13.57 (low $8.26, high $23.84) — a potential gain of +28% on today's $10.58. Momentum favours further upside here.
In 2029, EIKN is projected to trade between $9.36 and $31.17, averaging $16.69 — a potential gain of +58% from today's $10.58. That is up +23% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Eikon Therapeutics, Inc.'s 2030 outlook centres on $16.46, within a $8.54 to $32.29 range. That is -1% versus the projected 2029 average. That marks a +56% change versus current levels. Momentum favours further upside here.
By 2031, EIKN could reach as high as $32.21, with a base case around $15.73 and support toward $7.58 — roughly +49% from $10.58. Buyers look set to stay in control over this stretch.
Expect EIKN to range from $6.76 to $31.95 through 2032. The $15.03 average target implies a +42% move from current prices. That is -4% versus the projected 2031 average. Momentum favours further upside here.
The EIKN price prediction for 2033 points to an average of $15.78 (low $7.10, high $34.66) — a potential gain of +49% on today's $10.58. Buyers look set to stay in control over this stretch.
In 2034, EIKN is projected to trade between $7.45 and $37.49, averaging $16.56 — a potential gain of +57% from today's $10.58. That is up +5% on the projected 2033 average. Momentum favours further upside here.
Eikon Therapeutics, Inc.'s 2035 outlook centres on $20.55, within a $9.25 to $47.26 range. That is up +24% on the projected 2034 average. That marks a +94% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, EIKN could reach as high as $47.55, with a base case around $20.68 and support toward $9.30 — roughly +95% from $10.58. Momentum favours further upside here.
Expect EIKN to range from $21.28 to $108.79 through 2050. The $47.30 average target implies a +347% move from current prices. That is up +129% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in EIKN today (≈ 94.517958 EIKN) could be worth
$4,470.58
+$3,470.58 (+347%) by 2050 · US Dollar
Based on the average projected EIKN price of $47.3 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EIKNwould be worth at today's price.
$1,000 invested in EIKN on Feb 5, 2026 (≈ 66.666667 EIKN) would be worth
$705.33
-$294.67 (-29.5%) today · 0.71× · US Dollar
Based on a EIKN entry price of $15 vs. today's $10.58.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.54 | $843.7 | -15.6% |
| 1 month ago | $8.36 | $1,265.55 | +26.6% |
| 3 months ago | $9 | $1,175.56 | +17.6% |
| All time ago | $15 | $705.33 | -29.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EIKN forecast.
Our base-case forecast reaches $21.00 around 2050.
Implied market cap at $21.00: $1.14B
The multi-year forecast shows a gradual climb in average price from 2026 onward, with notable acceleration beginning in 2028 and continuing through 2050. The 2026 average is $10.72 with 0% ROI and NEUTRAL sentiment, followed by 2027 at $10.36 with -3.3% ROI and NEUTRAL sentiment. From 2028, the forecast turns bullish, with 2028 at $13.92 (29.9% ROI), 2029 at $17.15 (60% ROI), and 2030 at $16.67 (55.5% ROI).
The upward trajectory continues through 2031 ($16.08, 50% ROI), 2032 ($15.42, 43.9% ROI), 2033 ($15.97, 49% ROI), 2034 ($17.00, 58.6% ROI), and 2035 ($21.18, 97.5% ROI). By 2040 the average is $21.30 (98.7% ROI) and by 2050 the average reaches $48.61 with a max of $111.81 and a 353.5% ROI. The longer horizon carries bullish sentiment, but these are estimates and not guarantees, with substantial variability implied by the sharp rise in later years.
The numbers also reflect a high annualized volatility of 100%, underscoring the inherent uncertainty in long-range forecasts.
Tap a question to reveal the answer.
2030 min $8.56, avg $16.67, max $32.92; ROI 55.5%; sentiment BULLISH.
Forecasts show a bullish trend from 2028 onward, with positive ROIs in several years (e.g., 2028 29.9%, 2029 60%, 2030 55.5%), though 2027 shows a negative ROI of -3.3% and near-term volatility remains. The current price is $10.72 and the market cap is $580.37M.
The 2050 forecast shows an average of $48.61 and a maximum of $111.81, indicating $50 is within the longer-term range depending on the year and scenario.
RSI(14) is 50; SMA50 is $10.34. Support is at $8.36 and resistance at $13.05. The 30-day range runs from $7.69 to $14.94.
Market cap is $580.37M and the rank is 2934.
Eikon Therapeutics, Inc. Community Discussion
0Share your Eikon Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.